SCHEMBL15328558

SCHEMBL15328558

Cc1c2c(c(-c3cc([N+](=O)[O-])ccc3Oc3ccccc3)n1C)CCCC2=O

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 12/20 0.66
BRD2 P25440 1/20 0.42
SMARCA2 P51531 1/20 0.42
BRD3 Q15059 1/20 0.42
BRDT Q58F21 1/20 0.42
CREBBP Q92793 1/20 0.42
BRWD1 Q9NSI6 1/20 0.42
BAZ2A Q9UIF9 1/20 0.42
MAPT P10636 4/20 0.39
KMT2A Q03164 4/20 0.39
LMNA P02545 3/20 0.39
MEN1 O00255 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 2/20 0.39
CYP19A1 P11511 2/20 0.39
MLNR O43193 1/20 0.39
MMP1 P03956 1/20 0.39
MPO P05164 1/20 0.39
CYP1A2 P05177 1/20 0.39
GLA P06280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15328638 0.84 BRD4 (0.70) BRD4BRD2SMARCA2BRD3BRDT
SCHEMBL15328848 0.80 BRD4 (0.72) BRD4BRD2SMARCA2BRD3BRDT
SCHEMBL15328806 0.79 BRD4 (1.00) BRD4BRD2SMARCA2BRD3BRDT
SCHEMBL15328820 0.79 BRD4 (1.00) BRD4BRD2SMARCA2BRD3BRDT
SCHEMBL15524959 0.74 BRD4 (0.46) BRD4BRD2SMARCA2BRD3BRDT
SCHEMBL1553699 0.70 MAPT (0.57) BRD4MAPTKMT2ALMNAMEN1
SCHEMBL7885154 0.69 MAPT (0.56) BRD4MAPTKMT2ALMNAMEN1
SCHEMBL15550329 0.68 BRD4 (0.65) BRD4CREBBPMAPTKMT2ALMNA
SCHEMBL7885152 0.68 MAPT (0.54) BRD4MAPTKMT2ALMNAMEN1
SCHEMBL28337651 0.68 MEN1 (0.54) MAPTKMT2ALMNAMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2838881-B1 ISOINDOLONE DERIVATIVES ABBVIE INC (US) 2018-08-08 EP disclosed
US-9776990-B2 Isoindolone derivatives ABBVIE INC. (US) 2017-10-03 US disclosed
US-20150111890-A1 ISOINDOLONE DERIVATIVES ABBVIE INC. 2015-04-23 US disclosed
EP-2850071-A1 ISOINDOLONE DERIVATIVES AbbVie Inc. (US) 2015-03-25 EP disclosed
WO-2013158952-A1 ISOINDOLONE DERIVATIVES ABBVIE INC. (US) 2013-10-24 WO disclosed
US-20130281450-A1 ISOINDOLONE DERIVATIVES ABBVIE INC. 2013-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150111890-A1 ISOINDOLONE DERIVATIVES CYP11B1, HSD17B7, CYP4A11 BRD4 2626/4885BRD2 3083/4885SMARCA2 2016/4885
US-20130281450-A1 ISOINDOLONE DERIVATIVES CYP11B1, HSD17B7, CYP4A11 BRD4 2624/4885BRD2 3113/4885SMARCA2 2033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.